Product Images Edaravone
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 6 images provide visual information about the product associated with Edaravone NDC 39822-4510 by Xgen Pharmaceuticals Djb, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
30 mg carton - 30 mg carton photo
Description: A pharmaceutical product with the NDC code 39822-4500-2 is described in the text. It is an Edaravone Injection solution with a concentration of 0.3 mg/mL for intravenous infusion. The package contains two vials, each with a volume of 100mL. The recommended administration involves infusing the contents of each 100mL vial over a 30-minute period.*
30 mg vial - 30 mg vial photo
This is a label for Edaravone Injection, containing 30 mg of edaravone along with other inactive ingredients like L-cysteine hydrochloride hydrate. It is intended for intravenous infusion only, with a specific temperature requirement of 25°C (77°F). The text cautions to keep it away from children, not to swallow, and to discard any unused IV solution. The dosage instructions should be checked on the package insert for complete information.*
60 mg carton - 60 mg carton photo
The text is a medication label for Edaravone Injection with size specifications of 60 mg/100 ml and a concentration of 0.6 mg/mL for intravenous infusion. The product is identified by the NDC code 39822-4510-1. The text contains information related to dosage administration and storage instructions. The medication is likely used for specific medical purposes requiring exact dosing and administration guidelines.*
60 mg vial - 60 mg vial photo
This text provides important information about Edaravone Injection, including the NDC code (39822-4510-1), inactive ingredients, storage instructions, and dosage details. It also includes guidelines to not swallow the injection and to discard any unused IV solution. The text mentions the lot number and expiration date for tracking and verification purposes.*
edrv-structure - edrv structure
figure-1 - figure 1
This text provides information about the percentage of patients who experienced changes in their ALSFRS-R score after receiving Edaravone Injection compared to placebo at week 24. The data includes values representing patients who showed improvement or worsening of their condition.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
